European Biotechs Outperform, Here is the Proof

20/07/2015 - 2 minutes

We underwent great Biotech stories in 2014. However, was 2014 really a good year for the Biotech industry? EY released Beyond borders 2015, its 29th Biotechnology Industry Report. We summed up the most important details for you concerning the European Biotech sector. So, let’s go over a few statistics.


First impression, the Biotech industry is definitely blooming, showing an increase in revenues generated by the US and European commercial leaders starting from about $17b in 2000 to reach nearly $128b in 2014.development_biotech

In comparison to the previous year, revenues grew by 15%, most of all thanks to the European commercial leaders, who contributed to 77% of the annual revenue increase for 2014 alone. The net income mounts to a breathtaking 199% and the number of IPOs even raised by 288%, exposing Europe as a growing player in the Biotech industry.development_biotech

Seven of the top ten European commercial leaders with revenues of at least $500M per year have maintained their pole position since 2010.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!

Support Us

Become a Member